Navidea Biopharmaceuticals Inc (NAVB) Announces Quarterly Earnings Results
Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, Bloomberg Earnings reports. The business had revenue of $0.61 million during the quarter.
Shares of Navidea Biopharmaceuticals (NYSEMKT:NAVB) traded down 1.587% during midday trading on Thursday, hitting $0.403. The stock had a trading volume of 348,344 shares. The firm has a 50-day moving average of $0.47 and a 200 day moving average of $0.51. The firm has a market cap of $65.16 million and a PE ratio of 0.843. Navidea Biopharmaceuticals has a 12-month low of $0.26 and a 12-month high of $1.16.
WARNING: “Navidea Biopharmaceuticals Inc (NAVB) Announces Quarterly Earnings Results” was posted by Daily Political and is the property of of Daily Political. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/08/10/navidea-biopharmaceuticals-inc-navb-announces-quarterly-earnings-results.html.
Navidea Biopharmaceuticals Company Profile
Navidea Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease.
Receive News & Ratings for Navidea Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.